Sector
PharmaceuticalsOpen
₹1,636.95Prev. Close
₹1,672.55Turnover(Lac.)
₹809.34Day's High
₹1,710Day's Low
₹1,636.9552 Week's High
₹1,79952 Week's Low
₹900.05Book Value
₹145.8Face Value
₹1Mkt Cap (₹ Cr.)
17,493.92P/E
59.38EPS
28.13Divi. Yield
0.5223 May 2024
12:00 AM
AGM
Announcement Date: 23 May, 2024
14 Jun 2024
12:00 AM
BookCloser
15 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
23 May 2024
12:00 AM
Dividend
Dividend Amount: 8.75
Record Date: 22 Jun, 2024
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 10.46 | 10.46 | 9.51 | 9.51 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,514.79 | 1,281.52 | 1,097.65 | 990.16 |
Net Worth | 1,525.25 | 1,291.98 | 1,107.16 | 999.67 |
Minority Interest |
No Record found
No Record found
No Record found
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Gross Sales | 1,016.94 | 853.17 | 712.93 | 616.94 |
Excise Duty | 0 | 0 | 0 | 0 |
Net Sales | 1,016.94 | 853.17 | 712.93 | 616.94 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 37.15 | 37.27 | 23.42 | 13.81 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
SUDHIR JAIRAM VAID
Joint Managing Director & CEO
ANKUR VAID
Non Executive Director
Ravi Kapoor
Nominee
Rajiv Agarwal
Independent Director
BHARTI KHANNA
Independent Director
Amitabh Thakore
Independent Director
Arvind Agarwal
Independent Director
Jayaram Easwaran
Independent Director
Mandayam Chakravarthy Sriraman
Assistant VP (Finance) & CS
S Prakash
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Concord Biotech Ltd
Summary
Concord Biotech Ltd was originally incorporated as Servomed Pharmaceuticals Private Limited at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies. Thereafter, name of the Company was changed to Concord Biotech Limited dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC.The Company is an India-based biopharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immuno-suppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi, and formulations facility at Valthera in Gujarat.In 2000, the Company was acquired by the Promoter, Mr. Sudhir Vaid. In 2016, the Company launched formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States. It established a facility at Valthera, Gujarat.It set up a joint venture in Japan to grow business in 2018.In 2019, the Company received two ANDA approvals. It expanded their business into critical care segment in India.
Read More
What is the Concord Biotech Ltd share price today?
The Concord Biotech Ltd shares price on N/A is Rs.₹1667.1 today.
What is the Market Cap of Concord Biotech Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Concord Biotech Ltd is ₹17440.57 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Concord Biotech Ltd?
The PE and PB ratios of Concord Biotech Ltd is 59.38 and 11.46 as of 22 Jul ‘24
What is the 52 Week High and Low of Concord Biotech Ltd?
The 52-week high/low is the highest and lowest price at which a Concord Biotech Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Concord Biotech Ltd is ₹900 and ₹1793.5 as of 22 Jul ‘24
What is the CAGR of Concord Biotech Ltd?
Concord Biotech Ltd's CAGR for 5 Years at N/I%, 3 Years at N/I%, 1 Year at 77.36%, 6 Month at 20.38%, 3 Month at 4.71% and 1 Month at 6.10%.
What is the shareholding pattern of Concord Biotech Ltd?
The shareholding pattern of Concord Biotech Ltd is as follows:
Promoters - 44.08 %
Institutions - 17.51 %
Public - 38.41 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
